Emily Wendt

Emily Wendt is a seasoned research scientist with expertise in biomarker sciences and a focus on Inflammatory Bowel Disease (IBD). Currently serving as a Sr. Research Scientist II at Gilead Sciences since October 2015, Emily leads biomarker development for pre-clinical and clinical programs. Previously, Emily was a Postdoctoral Researcher at the University of Oxford, where research involved gut homing molecules in IBD using patient samples. Emily holds a DPhil in Clinical Medicine from the University of Oxford and a Bachelor of Science in Biological Sciences from the University of California, Davis. Earlier experience includes roles at ChemoCentryx supporting drug discovery, and internships at UCSF and AstraZeneca focusing on vaccine development.